Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sramek

Showing results (1-10 of 156) with videos related to

Pageof 16
Sort By:
Klinicheskaia Meditsina|July 1, 1989
[Risk factors in rheumatic fever]J Sramek
The American Journal of Psychiatry|June 1, 1988
Dosing practices for high- and low-potency neurolepticsG Hayes, J Sramek
Zhurnal Mikrobiologii, Epidemiologii I Immunobiologii|May 1, 1987
[Phage sensitivity of Streptococcus group A strains isolated in glomerulonephritis]T K Asoskova, J Sramek
The New England Journal of Medicine|July 23, 1981
"Loads"J J Sramek, A Khajawall
The American Journal of Psychiatry|February 1, 1982
Glutethimide abuseJ J Sramek, A Khajawall
Revue Neurologique|December 3, 1998
Exploratory studies: implications for drug development in Alzheimer's diseaseN R Cutler, J J Sramek
Expert Opinion on Investigational Drugs|November 4, 2000
Ongoing trials in Alzheimer's diseaseJ J Sramek, N R Cutler
Alzheimer Disease and Associated Disorders|February 24, 2001
RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?J J Sramek, N R Cutler
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 27, 2001
Review of the next generation of Alzheimer's disease therapeutics: challenges for drug developmentN R Cutler, J J Sramek
Current Topics in Behavioral Neurosciences|March 5, 2011
The impact of gender on antidepressantsJohn J Sramek, Neal R Cutler
Pageof 16

Showing results (1-10 of 156) with videos related to

Sort By:
Pageof 16
Klinicheskaia Meditsina|July 1, 1989
[Risk factors in rheumatic fever]J Sramek
The American Journal of Psychiatry|June 1, 1988
Dosing practices for high- and low-potency neurolepticsG Hayes, J Sramek
Zhurnal Mikrobiologii, Epidemiologii I Immunobiologii|May 1, 1987
[Phage sensitivity of Streptococcus group A strains isolated in glomerulonephritis]T K Asoskova, J Sramek
The New England Journal of Medicine|July 23, 1981
"Loads"J J Sramek, A Khajawall
The American Journal of Psychiatry|February 1, 1982
Glutethimide abuseJ J Sramek, A Khajawall
Revue Neurologique|December 3, 1998
Exploratory studies: implications for drug development in Alzheimer's diseaseN R Cutler, J J Sramek
Expert Opinion on Investigational Drugs|November 4, 2000
Ongoing trials in Alzheimer's diseaseJ J Sramek, N R Cutler
Alzheimer Disease and Associated Disorders|February 24, 2001
RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?J J Sramek, N R Cutler
Progress in Neuro-Psychopharmacology & Biological Psychiatry|March 27, 2001
Review of the next generation of Alzheimer's disease therapeutics: challenges for drug developmentN R Cutler, J J Sramek
Current Topics in Behavioral Neurosciences|March 5, 2011
The impact of gender on antidepressantsJohn J Sramek, Neal R Cutler
Pageof 16